These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27111121)

  • 1. Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.
    Staiger H; Schaeffeler E; Schwab M; Häring HU
    Rev Diabet Stud; 2015; 12(3-4):363-76. PubMed ID: 27111121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of Antidiabetic Drugs.
    Srinivasan S; Yee SW; Giacomini KM
    Adv Pharmacol; 2018; 83():361-389. PubMed ID: 29801583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
    Florez JC
    Diabetologia; 2017 May; 60(5):800-807. PubMed ID: 28283684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of metformin response: a step in the path toward personalized medicine.
    Reitman ML; Schadt EE
    J Clin Invest; 2007 May; 117(5):1226-9. PubMed ID: 17476355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine: The future in diabetes care?
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Jul; 117():12-21. PubMed ID: 27329017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenetics of oral antidiabetic treatment].
    Tkáč I
    Vnitr Lek; 2016 Mar; 62(3):186-8. PubMed ID: 27180666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions of clinical importance with antihyperglycaemic agents: an update.
    Scheen AJ
    Drug Saf; 2005; 28(7):601-31. PubMed ID: 15963007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.
    Glamočlija U; Jevrić-Čaušević A
    Acta Pharm; 2010 Dec; 60(4):387-406. PubMed ID: 21169132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.
    Mannino GC; Andreozzi F; Sesti G
    Diabetes Metab Res Rev; 2019 Mar; 35(3):e3109. PubMed ID: 30515958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review of the Impact of Pharmacogenetics and Metabolomics on the Efficacy of Metformin in Type 2 Diabetes.
    Damanhouri ZA; Alkreathy HM; Alharbi FA; Abualhamail H; Ahmad MS
    Int J Med Sci; 2023; 20(1):142-150. PubMed ID: 36619226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
    Abbatecola AM; Maggi S; Paolisso G
    Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs.
    Chakraborty C; Hsu MJ; Agoramoorthy G
    Curr Drug Metab; 2015; 16(10):864-76. PubMed ID: 26652255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.
    Fisman EZ; Motro M; Tenenbaum A
    Adv Cardiol; 2008; 45():154-170. PubMed ID: 18230961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metformin transporter pharmacogenomics: insights into drug disposition-where are we now?
    Chan P; Shao L; Tomlinson B; Zhang Y; Liu ZM
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1149-1159. PubMed ID: 30375241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?
    Emami-Riedmaier A; Schaeffeler E; Nies AT; Mörike K; Schwab M
    J Intern Med; 2015 Feb; 277(2):235-247. PubMed ID: 25418285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the pharmacogenomics of metformin: progress, problems and potential.
    Todd JN; Florez JC
    Pharmacogenomics; 2014 Mar; 15(4):529-39. PubMed ID: 24624919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and personalized treatment of type 2 diabetes.
    Semiz S; Dujic T; Causevic A
    Biochem Med (Zagreb); 2013; 23(2):154-71. PubMed ID: 23894862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.